Creso Pharma is looking to increase revenue from nutraceuticals and animal health products as part of its renewed strategy. The ASX cannabis group expects to generate more than $3.6 million in revenue in CY 2019 from the segment.
Cost management was highlighted as a priority as Creso Pharma looks to reduce its monthly cash burn.
- Forums
- ASX - By Stock
- CPH
- Ann: Reinstatement to Official Quotation
Ann: Reinstatement to Official Quotation, page-22
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress